Reviews Icodextrin Peritoneal Dialysis Solution


No reviews yet.

Extraneal Drug Description
Extraneal
(icodextrin) Peritoneal Dialysis Solution

Dangerous Drug-Device Interaction
Only use glucose-specific monitors and test strips to measure blood glucose
levels in patients using Extraneal (icodextrin) Peritoneal Dialysis Solution.
Blood glucose monitoring devices using glucose dehydrogenase pyrroloquinolinequinone
(GDH-PQQ) or glucose-dye-oxidoreductase (GDO)-based methods must not be used.
Use of GDH-PQQ or GDO-based glucose monitors and test strips has resulted
in falsely elevated glucose readings (due to the presence of maltose, see
PRECAUTIONS/Drug/Laboratory Test Interactions)
and has led patients or health care providers to withhold treatment of hypoglycemia
or to administer insulin inappropriately. Both of these situations have resulted
in unrecognized hypoglycemia, which has led to loss of consciousness, coma,
permanent neurological damage, and death. Plasma levels of Extraneal (icodextrin)
and its metabolites return to baseline within approximately 14 days following
cessation of Extraneal (icodextrin) administration. Therefore falsely elevated
glucose levels may be measured up to two weeks following cessation of Extraneal
(icodextrin) therapy when GDH-PQQ or GDO-based blood glucose monitors and
test strips are used.
Because GDH-PQQ and GDO-based blood glucose monitors may be used in hospital settings, it is important that the health care providers of peritoneal dialysis patients using Extraneal (icodextrin) carefully review the product information of the blood glucose testing system, including that of test strips, to determine if the system is appropriate for use with Extraneal (icodextrin).
To avoid improper insulin administration, educate patients to alert health care providers of this interaction whenever they are admitted to the hospital.
Information regarding glucose monitor and test strip methodology can be obtained
from their manufacturers. For a list of toll free numbers for glucose monitor
and test strip manufacturers, please contact the Baxter Renal Clinical Help
Line 1-888-RENAL-HELP or visit www.glucosesafety.com.

DRUG DESCRIPTION
Extraneal (icodextrin) Peritoneal Dialysis Solution is a peritoneal dialysis
solution containing the colloid osmotic agent icodextrin. Icodextrin is a starch-derived,
water-soluble glucose polymer linked by alpha (1-4) and less than 10% alpha
(1-6) glucosidic bonds with a weight-average molecular weight between 13,000
and 19,000 Daltons and a number average molecular weight between 5,000 and 6,500
Daltons. The representative structural formula of icodextrin is:











Each 100 mL of Extraneal contains:


Icodextrin
7.5 g


Sodium Chloride, USP
535 mg


Sodium Lactate
448 mg


Calcium Chloride, USP
25.7 mg


Magnesium Chloride, USP
5.08 mg






Electrolyte content per liter:


Sodium
132 mEq/L


Calcium
3.5 mEq/L


Magnesium
0.5 mEq/L


Chloride
96 mEq/L


Lactate
40 mEq/L


Water for Injection, USP qs
HCl/NaOH may have been used to adjust pH.
Extraneal contains no bacteriostatic or antimicrobial agents.
Calculated osmolarity: 282–286 mOsm/L; pH=5.0-6.0
Extraneal is available for intraperitoneal administration only as a sterile, nonpyrogenic, clear solution in 1.5 L, 2.0 L and 2.5 L AMBU-FLEX III and ULTRABAG containers. The container systems are composed of polyvinyl chloride.
Solutions in contact with the plastic container can leach out certain of its
chemical components in very small amounts within the expiration period, e.g.,
di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety
of the plastic has been confirmed in tests in animals according to USP biological
tests for plastic containers as well as by tissue culture toxicity studies.Last reviewed on RxList: 4/30/2009




Extraneal Drug Description
Extraneal
(icodextrin) Peritoneal Dialysis Solution

Dangerous Drug-Device Interaction
Only use glucose-specific monitors and test strips to measure blood glucose
levels in patients using Extraneal (icodextrin) Peritoneal Dialysis Solution.
Blood glucose monitoring devices using glucose dehydrogenase pyrroloquinolinequinone
(GDH-PQQ) or glucose-dye-oxidoreductase (GDO)-based methods must not be used.
Use of GDH-PQQ or GDO-based glucose monitors and test strips has resulted
in falsely elevated glucose readings (due to the presence of maltose, see
PRECAUTIONS/Drug/Laboratory Test Interactions)
and has led patients or health care providers to withhold treatment of hypoglycemia
or to administer insulin inappropriately. Both of these situations have resulted
in unrecognized hypoglycemia, which has led to loss of consciousness, coma,
permanent neurological damage, and death. Plasma levels of Extraneal (icodextrin)
and its metabolites return to baseline within approximately 14 days following
cessation of Extraneal (icodextrin) administration. Therefore falsely elevated
glucose levels may be measured up to two weeks following cessation of Extraneal
(icodextrin) therapy when GDH-PQQ or GDO-based blood glucose monitors and
test strips are used.
Because GDH-PQQ and GDO-based blood glucose monitors may be used in hospital settings, it is important that the health care providers of peritoneal dialysis patients using Extraneal (icodextrin) carefully review the product information of the blood glucose testing system, including that of test strips, to determine if the system is appropriate for use with Extraneal (icodextrin).
To avoid improper insulin administration, educate patients to alert health care providers of this interaction whenever they are admitted to the hospital.
Information regarding glucose monitor and test strip methodology can be obtained
from their manufacturers. For a list of toll free numbers for glucose monitor
and test strip manufacturers, please contact the Baxter Renal Clinical Help
Line 1-888-RENAL-HELP or visit www.glucosesafety.com.

DRUG DESCRIPTION
Extraneal (icodextrin) Peritoneal Dialysis Solution is a peritoneal dialysis
solution containing the colloid osmotic agent icodextrin. Icodextrin is a starch-derived,
water-soluble glucose polymer linked by alpha (1-4) and less than 10% alpha
(1-6) glucosidic bonds with a weight-average molecular weight between 13,000
and 19,000 Daltons and a number average molecular weight between 5,000 and 6,500
Daltons. The representative structural formula of icodextrin is:











Each 100 mL of Extraneal contains:


Icodextrin
7.5 g


Sodium Chloride, USP
535 mg


Sodium Lactate
448 mg


Calcium Chloride, USP
25.7 mg


Magnesium Chloride, USP
5.08 mg






Electrolyte content per liter:


Sodium
132 mEq/L


Calcium
3.5 mEq/L


Magnesium
0.5 mEq/L


Chloride
96 mEq/L


Lactate
40 mEq/L


Water for Injection, USP qs
HCl/NaOH may have been used to adjust pH.
Extraneal contains no bacteriostatic or antimicrobial agents.
Calculated osmolarity: 282–286 mOsm/L; pH=5.0-6.0
Extraneal is available for intraperitoneal administration only as a sterile, nonpyrogenic, clear solution in 1.5 L, 2.0 L and 2.5 L AMBU-FLEX III and ULTRABAG containers. The container systems are composed of polyvinyl chloride.
Solutions in contact with the plastic container can leach out certain of its
chemical components in very small amounts within the expiration period, e.g.,
di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety
of the plastic has been confirmed in tests in animals according to USP biological
tests for plastic containers as well as by tissue culture toxicity studies.Last reviewed on RxList: 4/30/2009




Extraneal Drug Description
Extraneal
(icodextrin) Peritoneal Dialysis Solution

Dangerous Drug-Device Interaction
Only use glucose-specific monitors and test strips to measure blood glucose
levels in patients using Extraneal (icodextrin) Peritoneal Dialysis Solution.
Blood glucose monitoring devices using glucose dehydrogenase pyrroloquinolinequinone
(GDH-PQQ) or glucose-dye-oxidoreductase (GDO)-based methods must not be used.
Use of GDH-PQQ or GDO-based glucose monitors and test strips has resulted
in falsely elevated glucose readings (due to the presence of maltose, see
PRECAUTIONS/Drug/Laboratory Test Interactions)
and has led patients or health care providers to withhold treatment of hypoglycemia
or to administer insulin inappropriately. Both of these situations have resulted
in unrecognized hypoglycemia, which has led to loss of consciousness, coma,
permanent neurological damage, and death. Plasma levels of Extraneal (icodextrin)
and its metabolites return to baseline within approximately 14 days following
cessation of Extraneal (icodextrin) administration. Therefore falsely elevated
glucose levels may be measured up to two weeks following cessation of Extraneal
(icodextrin) therapy when GDH-PQQ or GDO-based blood glucose monitors and
test strips are used.
Because GDH-PQQ and GDO-based blood glucose monitors may be used in hospital settings, it is important that the health care providers of peritoneal dialysis patients using Extraneal (icodextrin) carefully review the product information of the blood glucose testing system, including that of test strips, to determine if the system is appropriate for use with Extraneal (icodextrin).
To avoid improper insulin administration, educate patients to alert health care providers of this interaction whenever they are admitted to the hospital.
Information regarding glucose monitor and test strip methodology can be obtained
from their manufacturers. For a list of toll free numbers for glucose monitor
and test strip manufacturers, please contact the Baxter Renal Clinical Help
Line 1-888-RENAL-HELP or visit www.glucosesafety.com.

DRUG DESCRIPTION
Extraneal (icodextrin) Peritoneal Dialysis Solution is a peritoneal dialysis
solution containing the colloid osmotic agent icodextrin. Icodextrin is a starch-derived,
water-soluble glucose polymer linked by alpha (1-4) and less than 10% alpha
(1-6) glucosidic bonds with a weight-average molecular weight between 13,000
and 19,000 Daltons and a number average molecular weight between 5,000 and 6,500
Daltons. The representative structural formula of icodextrin is:











Each 100 mL of Extraneal contains:


Icodextrin
7.5 g


Sodium Chloride, USP
535 mg


Sodium Lactate
448 mg


Calcium Chloride, USP
25.7 mg


Magnesium Chloride, USP
5.08 mg






Electrolyte content per liter:


Sodium
132 mEq/L


Calcium
3.5 mEq/L


Magnesium
0.5 mEq/L


Chloride
96 mEq/L


Lactate
40 mEq/L


Water for Injection, USP qs
HCl/NaOH may have been used to adjust pH.
Extraneal contains no bacteriostatic or antimicrobial agents.
Calculated osmolarity: 282–286 mOsm/L; pH=5.0-6.0
Extraneal is available for intraperitoneal administration only as a sterile, nonpyrogenic, clear solution in 1.5 L, 2.0 L and 2.5 L AMBU-FLEX III and ULTRABAG containers. The container systems are composed of polyvinyl chloride.
Solutions in contact with the plastic container can leach out certain of its
chemical components in very small amounts within the expiration period, e.g.,
di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety
of the plastic has been confirmed in tests in animals according to USP biological
tests for plastic containers as well as by tissue culture toxicity studies.Last reviewed on RxList: 4/30/2009




Extraneal Drug Description
Extraneal
(icodextrin) Peritoneal Dialysis Solution

Dangerous Drug-Device Interaction
Only use glucose-specific monitors and test strips to measure blood glucose
levels in patients using Extraneal (icodextrin) Peritoneal Dialysis Solution.
Blood glucose monitoring devices using glucose dehydrogenase pyrroloquinolinequinone
(GDH-PQQ) or glucose-dye-oxidoreductase (GDO)-based methods must not be used.
Use of GDH-PQQ or GDO-based glucose monitors and test strips has resulted
in falsely elevated glucose readings (due to the presence of maltose, see
PRECAUTIONS/Drug/Laboratory Test Interactions)
and has led patients or health care providers to withhold treatment of hypoglycemia
or to administer insulin inappropriately. Both of these situations have resulted
in unrecognized hypoglycemia, which has led to loss of consciousness, coma,
permanent neurological damage, and death. Plasma levels of Extraneal (icodextrin)
and its metabolites return to baseline within approximately 14 days following
cessation of Extraneal (icodextrin) administration. Therefore falsely elevated
glucose levels may be measured up to two weeks following cessation of Extraneal
(icodextrin) therapy when GDH-PQQ or GDO-based blood glucose monitors and
test strips are used.
Because GDH-PQQ and GDO-based blood glucose monitors may be used in hospital settings, it is important that the health care providers of peritoneal dialysis patients using Extraneal (icodextrin) carefully review the product information of the blood glucose testing system, including that of test strips, to determine if the system is appropriate for use with Extraneal (icodextrin).
To avoid improper insulin administration, educate patients to alert health care providers of this interaction whenever they are admitted to the hospital.
Information regarding glucose monitor and test strip methodology can be obtained
from their manufacturers. For a list of toll free numbers for glucose monitor
and test strip manufacturers, please contact the Baxter Renal Clinical Help
Line 1-888-RENAL-HELP or visit www.glucosesafety.com.

DRUG DESCRIPTION
Extraneal (icodextrin) Peritoneal Dialysis Solution is a peritoneal dialysis
solution containing the colloid osmotic agent icodextrin. Icodextrin is a starch-derived,
water-soluble glucose polymer linked by alpha (1-4) and less than 10% alpha
(1-6) glucosidic bonds with a weight-average molecular weight between 13,000
and 19,000 Daltons and a number average molecular weight between 5,000 and 6,500
Daltons. The representative structural formula of icodextrin is:











Each 100 mL of Extraneal contains:


Icodextrin
7.5 g


Sodium Chloride, USP
535 mg


Sodium Lactate
448 mg


Calcium Chloride, USP
25.7 mg


Magnesium Chloride, USP
5.08 mg






Electrolyte content per liter:


Sodium
132 mEq/L


Calcium
3.5 mEq/L


Magnesium
0.5 mEq/L


Chloride
96 mEq/L


Lactate
40 mEq/L


Water for Injection, USP qs
HCl/NaOH may have been used to adjust pH.
Extraneal contains no bacteriostatic or antimicrobial agents.
Calculated osmolarity: 282–286 mOsm/L; pH=5.0-6.0
Extraneal is available for intraperitoneal administration only as a sterile, nonpyrogenic, clear solution in 1.5 L, 2.0 L and 2.5 L AMBU-FLEX III and ULTRABAG containers. The container systems are composed of polyvinyl chloride.
Solutions in contact with the plastic container can leach out certain of its
chemical components in very small amounts within the expiration period, e.g.,
di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety
of the plastic has been confirmed in tests in animals according to USP biological
tests for plastic containers as well as by tissue culture toxicity studies.Last reviewed on RxList: 4/30/2009




Extraneal Drug Description
Extraneal
(icodextrin) Peritoneal Dialysis Solution

Dangerous Drug-Device Interaction
Only use glucose-specific monitors and test strips to measure blood glucose
levels in patients using Extraneal (icodextrin) Peritoneal Dialysis Solution.
Blood glucose monitoring devices using glucose dehydrogenase pyrroloquinolinequinone
(GDH-PQQ) or glucose-dye-oxidoreductase (GDO)-based methods must not be used.
Use of GDH-PQQ or GDO-based glucose monitors and test strips has resulted
in falsely elevated glucose readings (due to the presence of maltose, see
PRECAUTIONS/Drug/Laboratory Test Interactions)
and has led patients or health care providers to withhold treatment of hypoglycemia
or to administer insulin inappropriately. Both of these situations have resulted
in unrecognized hypoglycemia, which has led to loss of consciousness, coma,
permanent neurological damage, and death. Plasma levels of Extraneal (icodextrin)
and its metabolites return to baseline within approximately 14 days following
cessation of Extraneal (icodextrin) administration. Therefore falsely elevated
glucose levels may be measured up to two weeks following cessation of Extraneal
(icodextrin) therapy when GDH-PQQ or GDO-based blood glucose monitors and
test strips are used.
Because GDH-PQQ and GDO-based blood glucose monitors may be used in hospital settings, it is important that the health care providers of peritoneal dialysis patients using Extraneal (icodextrin) carefully review the product information of the blood glucose testing system, including that of test strips, to determine if the system is appropriate for use with Extraneal (icodextrin).
To avoid improper insulin administration, educate patients to alert health care providers of this interaction whenever they are admitted to the hospital.
Information regarding glucose monitor and test strip methodology can be obtained
from their manufacturers. For a list of toll free numbers for glucose monitor
and test strip manufacturers, please contact the Baxter Renal Clinical Help
Line 1-888-RENAL-HELP or visit www.glucosesafety.com.

DRUG DESCRIPTION
Extraneal (icodextrin) Peritoneal Dialysis Solution is a peritoneal dialysis
solution containing the colloid osmotic agent icodextrin. Icodextrin is a starch-derived,
water-soluble glucose polymer linked by alpha (1-4) and less than 10% alpha
(1-6) glucosidic bonds with a weight-average molecular weight between 13,000
and 19,000 Daltons and a number average molecular weight between 5,000 and 6,500
Daltons. The representative structural formula of icodextrin is:











Each 100 mL of Extraneal contains:


Icodextrin
7.5 g


Sodium Chloride, USP
535 mg


Sodium Lactate
448 mg


Calcium Chloride, USP
25.7 mg


Magnesium Chloride, USP
5.08 mg






Electrolyte content per liter:


Sodium
132 mEq/L


Calcium
3.5 mEq/L


Magnesium
0.5 mEq/L


Chloride
96 mEq/L


Lactate
40 mEq/L


Water for Injection, USP qs
HCl/NaOH may have been used to adjust pH.
Extraneal contains no bacteriostatic or antimicrobial agents.
Calculated osmolarity: 282–286 mOsm/L; pH=5.0-6.0
Extraneal is available for intraperitoneal administration only as a sterile, nonpyrogenic, clear solution in 1.5 L, 2.0 L and 2.5 L AMBU-FLEX III and ULTRABAG containers. The container systems are composed of polyvinyl chloride.
Solutions in contact with the plastic container can leach out certain of its
chemical components in very small amounts within the expiration period, e.g.,
di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety
of the plastic has been confirmed in tests in animals according to USP biological
tests for plastic containers as well as by tissue culture toxicity studies.Last reviewed on RxList: 4/30/2009





Other reviews about Icodextrin Peritoneal Dialysis Solution on wordpress

Baxter - Business
  by El Horror
About - 1980's: Contaminated hemophilia blood products infected HIV and Hepatitis C worldwide. - 2001: Malfunctioning dialysis machines resulted in several deaths in Spain. - 2008: Intentional contaminated heparin processed in […]



Other reviews about Icodextrin Peritoneal Dialysis Solution on web:

EXTRANEAL (icodextrin) Peritoneal Dialysis Solution 07-19-59-402 Dangerous Drug-Device Interaction Only use glucose-specific monitors and test strips to measure blood glucose ... EXTRANEAL (icodextrin) Peritoneal Dialysis Solution


Learn about the prescription medication Extraneal (Icodextrin Peritoneal Dialysis Solution), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient ... Extraneal (Icodextrin Peritoneal Dialysis Solution) Drug ...


Hospital Pharmacy 669 FORMULARY DRUG REVIEWS Hospital Pharmacy Volume 38, Number 7, pp 669-677 2003 Wolters Kluwer Health, Inc. Icodextrin Peritoneal Dialysis Solution Dennis J. Cada ... Icodextrin Peritoneal Dialysis Solution


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- April 2009 Extraneal (icodextrin) Peritoneal Dialysis Solution April 2009


FDA Approves New Peritoneal Dialysis Solution Extraneal (Icodextrin) News - FDA Approves New Peritoneal Dialysis Solution Extraneal ...


NDA 21-321/S-017 Page 3 Extraneal (icodextrin) Peritoneal Dialysis Solution Dangerous Drug-Device Interaction Only use glucose-specific monitors and test strips to measure blood glucose ... Dangerous Drug-Device Interaction


Icodextrin is a peritoneal dialysis solution containing the colloid osmotic agent icodextrin. Icodextrin is a starch-derived, water-soluble glucose polymer linked by alpha (1-4) and ... Icodextrin - Wikipedia, the free encyclopedia


Examine the benefits of a unique, non-glucose, osmotic agent. Unique mechanism of action; Enhances ultrafiltration and fluid management; Decreases carbohydrate absorption and caloric load EXTRANEAL (Icodextrin) Peritoneal Dialysis Solution


EXTRANEAL (icodextrin) Peritoneal Dialysis (PD) Solution. Dangerous Drug-Device Interaction. Only use glucose-specific monitors ... Baxter PD Solutions - Extraneal


Plum J, Gentile S, Verger C, Brunkhorst R, Bahner U, Faller B, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated ... ICODEXTRIN METABOLITES IN PERITONEAL DIALYSIS -- García–López ...





Featured Reviews

Reviews Triamcinolone Acetonide Injectable Suspension

Trivaris Drug Description TRIVARIS™ (triamcinolone acetonide) Injectable Suspension 80 mg/mL DRUG DESCRIPTION What are the possible side effects of triamcinolone injection? Get emergency medical help if you have any of these...
Read More  |  Review This
Reviews ASUS Zenbook UX305FA-ASM1 13.3-Inch Ultra-Slim Aluminum Laptop, 8 GB RAM and 256 GB SSD

Wow! Thoroughly impressed by this ultrabook. At $699, this is a steal. I've been using it for 1 day so far, so these are my first impressions. TL;DR: At $699, this is a steal. Works great as a linux laptop. 10/10 machine. Linux Compatibility...
Read More  |  Review This
Reviews Follitropin Beta Injection

Follistim AQ Cartridge Drug Description Follistim® AQ Cartridge (follitropin beta) Injection FOR SUBCUTANEOUS USE ONLY DRUG DESCRIPTION What are the possible side effects of follicle stimulating hormone (Follistim, Follistim...
Read More  |  Review This
Reviews Prostigmin

Prostigmin Drug Description PROSTIGMIN® (neostigmine bromide) Tablets DRUG DESCRIPTION What are the possible side effects of neostigmine (Prostigmin Bromide)? Get emergency medical help if you have any of these signs of an...
Read More  |  Review This
Reviews Phenazopyridine

Pyridium Drug Description Pyridium® (phenazopyridine HCl) Tablets, USP DRUG DESCRIPTION What are the possible side effects of phenazopyridine? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....